MDM2 binds and inhibits vitamin D receptor

Cell Cycle

Volumn 14, Issue 13, 2015, Pages 2003-2010

  Heyne, Kristina ^a   Heil, Tessa Carina ^a   Bette, Birgit ^a   Reichrath, Jörg ^a   Roemer, Klaus ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

MDM2; Transcription; Tumor suppression; Vitamin D; Vitamin D receptor

Indexed keywords

COLECALCIFEROL 24 HYDROXYLASE; CYCLIN DEPENDENT KINASE INHIBITOR 1A; PROTEIN BAX; PROTEIN BCL 2; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; PROTEIN P63; VITAMIN D RECEPTOR; CALCITRIOL RECEPTOR; MDM2 PROTEIN, HUMAN; PROTEIN BINDING;

AMINO TERMINAL SEQUENCE; APOPTOSIS; ARTICLE; CELL AGING; CELL CYCLE ARREST; CELL DIFFERENTIATION; CONTROLLED STUDY; DNA BINDING; HOMOZYGOSITY; HUMAN; HUMAN CELL; PROMOTER REGION; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REPORTER GENE; SENESCENCE; STEADY STATE; TRANSACTIVATION; TRANSIENT TRANSFECTION; UBIQUITINATION; ANTAGONISTS AND INHIBITORS; CELL LINE; METABOLISM; PHYSIOLOGY;

CELL LINE; HUMANS; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-MDM2; RECEPTORS, CALCITRIOL;

EID: 84943759073     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.1080/15384101.2015.1044176     Document Type: Article

References (35)

1. Zhang J, Chalmers MJ, Stayrook KR, Burris LL, Wang Y, Busby SA, Pascal BD, Garcia-Ordonez RD, Bruning JB, Istrate MA, et al. DNA binding alters coactivator interaction surfaces of the intact VDR-RXR complex. Nat Struct Mol Biol 2011; 18: 556-63.; PMID: 21478866; http://dx. doi. org/10. 1038/nsmb. 2046.
2. Rochel N, Ciesielski F, Godet J, Moman E, Roessle M, Peluso-Iltis C, Moulin M, Haertlein M, Callow P, Mély Y, et al. Common architecture of nuclear receptor heterodimers on DNA direct repeat elements with different spacings. Nat Struct Mol Biol 2011; 18: 564-70.; PMID: 21478865; http://dx. doi. org/10. 1038/nsmb. 2054.
3. Murayama A, Kim MS, Yanagisawa J, Takeyama K, Kato S. Transrepression by a liganded nuclear receptor via a bHLH activator through co-regulator switching. EMBO J 2004; 23: 1598-608.; PMID: 15934135; http://dx. doi. org/10. 1038/sj. emboj. 7600157.
4. Kim MS, Fujiki R, Kitagawa H, Kato S. 1alpha, 25 (OH)2D3-induced DNA methylation suppresses the human CYP27B1 gene. Mol Cell Endocrinol 2007; 265-266: 168-73.; PMID: 17250953.
5. Meyer MB, Goetsch PD, Pike JW. VDR/RXR and TCF4/beta-catenin cistromes in colonic cells of colorectal tumor origin: impact on c-FOS and c-MYC gene expression. Mol Endocrinol 2012; 26: 37-51.; PMID: AMBIGUOUS; http://dx. doi. org/10. 1210/me. 2011-1109.
6. Pike JW, Meyer MB. Fundamentals of vitamin D hormone-regulated gene expression. J Steroid Biochem Mol Biol 2013; 144: 5-11.; PMID: 24239506; http://dx. doi. org/10. 1016/j. jsbmb. 2013. 11. 004.
7. Iwakuma T, Lozano G. MDM2, an introduction. Mol Cancer Res 2003; 1: 993-1000.; PMID: 14707282.
8. Meek DW, Knippschild U. Posttranslational modification of MDM2. Mol Cancer Res 2003; 1: 1017-26.; PMID: 14707285.
9. Wade M, Wang YV, Wahl GM. The p53 orchestra: Mdm2 and Mdmx set the tone. Trends 2010; 20: 299-309. Epub 2010 Feb 19.; PMID: NOT_FOUND.
10. Heyne K, Winter C, Gerten F, Schmidt C, Roemer K. A novel mechanism of crosstalk between the p53 and NFkappaB pathways: MDM2 binds and inhibits p65RelA. Cell Cycle 2013; 12: 2479-92.; PMID: 23839035; http://dx. doi. org/10. 4161/cc. 25495.
11. Barak Y, Gottlieb E, Juven-Gershon T, Oren M. Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential. Genes Dev 1994; 8: 1739-49.; PMID: 7958853; http://dx. doi. org/10. 1101/gad. 8. 15. 1739.
12. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997; 387: 296-9.; PMID: 9153395; http://dx. doi. org/10. 1038/387296a0.
13. Ohtsubo C, Shiokawa D, Kodama M, Gaiddon C, Nakagama H, Jochemsen AG, Taya Y, Okamoto K. Cytoplasmic tethering is involved in synergistic inhibition of p53 by Mdmx and Mdm2. Cancer Sci 2009; 100: 1291-9.; PMID: 19432880; http://dx. doi. org/10. 1111/j. 1349-7006. 2009. 01180. x.
14. D protein. Genes Dev 1994; 8: 1235-46.; PMID: 7926727; http://dx. doi. org/10. 1101/gad. 8. 10. 1235.
15. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997; 387: 299-303.; PMID: 9153396; http://dx. doi. org/10. 1038/387299a0.
16. Thut CJ, Goodrich JA, Tjian R. Repression of p53-mediated transcription by MDM2: a dual mechanism. Genes Dev 1997; 11: 1974-86.; PMID: 9271120; http://dx. doi. org/10. 1101/gad. 11. 15. 1974.
17. Wu X, Bayle JH, Olson D, Levine AJ. The p53-mdm-2 autoregulatory feedback loop. Genes Dev 1993; 7: 1126-32.; PMID: 8319905; http://dx. doi. org/10. 1101/gad. 7. 7a. 1126.
18. Chen H, Reed G, Guardia J, Lakhan S, Couture O, Hays E, Chandar N. Vitamin D directly regulates Mdm2 gene expression in osteoblasts. Biochem Biophys Res Commun 2013; 430: 370-4.; PMID: 23149414; http://dx. doi. org/10. 1016/j. bbrc. 2012. 11. 003.
19. Wang Y, Zhu J, DeLuca HF. Where is the vitamin D receptor? Arch Biochem Biophys 2012; 523: 123-33.; PMID: 22503810; http://dx. doi. org/10. 1016/j. abb. 2012. 04. 001.
20. Zou A, Elgort MG, Allegretto EA. Retinoid X receptor (RXR) ligands activate the human 25-hydroxyvitamin D3-24-hydroxylase promoter via RXR heterodimer binding to two vitamin D-responsive elements and elicit additive effects with 1, 25-dihydroxyvitamin D3. J Biol Chem 1997; 272: 19027-34.; PMID: 9228086; http://dx. doi. org/10. 1074/jbc. 272. 30. 19027.
21. Liu M, Lee MH, Cohen M, Bommakanti M, Freedman LP. Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev 1996; 10: 142-53.; PMID: 8566748; http://dx. doi. org/10. 1101/gad. 10. 2. 142.
22. Haussler MR, Haussler CA, Bartik L, Whitfield GK, Hsieh JC, Slater S, Jurutka PW. Vitamin D receptor: molecular signaling and actions of nutritional ligands in disease prevention. Nutr Rev 2008; 66: S98-112.; PMID: 18844852; http://dx. doi. org/10. 1111/j. 1753-4887. 2008. 00093. x.
23. Feldman D, Krishnan AV, Swami S, Giovannucci E, Feldman BJ. The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer 2014; 14: 342-57.; PMID: 24705652; http://dx. doi. org/10. 1038/nrc3691.
24. Reichrath J, Reichrath S, Heyne K, Vogt T, Roemer K. Tumor suppression in skin and other tissues via crosstalk between vitamin D-and p53-signaling. Front Physiol 2014; 5: 166.; PMID: 24917821; http://dx. doi. org/10. 3389/fphys. 2014. 00166.
25. Kommagani R, Payal V, Kadakia MP. Differential regulation of vitamin D receptor (VDR) by the p53 Family: p73-dependent induction of VDR upon DNA damage. J Biol Chem 2007; 282: 29847-54.; PMID: 17716971; http://dx. doi. org/10. 1074/jbc. M703641200.
26. Maruyama R, Aoki F, Toyota M, Sasaki Y, Akashi H, Mita H, Suzuki H, Akino K, Ohe-Toyota M, Maruyama Y, et al. Comparative genome analysis identifies the vitamin D receptor gene as a direct target of p53-mediated transcriptional activation. Cancer Res 2006; 66: 4574-83.; PMID: 16651407; http://dx. doi. org/10. 1158/0008-5472. CAN-05-2562.
27. Skowronski RJ, Peehl DM, Feldman D. Vitamin D and prostate cancer: 1, 25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology 1993; 132: 1952-60.; PMID: 7682937.
28. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992; 358: 80-3.; PMID: 1614537; http://dx. doi. org/10. 1038/358080a0.
29. Bueso-Ramos CE, Yang Y, deLeon E, McCown P, Stass SA, Albitar M. The human MDM-2 oncogene is overexpressed in leukemias. Blood 1993; 82: 2617-23.; PMID: 8219216.
30. Watanabe T, Hotta T, Ichikawa A, Kinoshita T, Nagai H, Uchida T, Murate T, Saito H. The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin. Blood 1994; 84: 3158-65.; PMID: 7949188.
31. Sheikh MS, Shao ZM, Hussain A, Fontana JA. The p53-binding protein MDM2 gene is differentially expressed in human breast carcinoma. Cancer Res 1993; 53: 3226-8.; PMID: 8324731.
32. Reifenberger G, Liu L, Ichimura K, Schmidt EE, Collins VP. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 1993; 53: 2736-9.; PMID: 8504413.
33. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004; 119: 591-602.; PMID: 15550242; http://dx. doi. org/10. 1016/j. cell. 2004. 11. 022.
34. Post SM, Quintas-Cardama A, Pant V, Iwakuma T, Hamir A, Jackson JG, Maccio DR, Bond GL, Johnson DG, Levine AJ, et al. A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development. Cancer Cell 2010; 18: 220-30.; PMID: 20832750; http://dx. doi. org/10. 1016/j. ccr. 2010. 07. 010.
35. Heyne K, Forster J, Schule R, Roemer K. Transcriptional repressor NIR interacts with the p53-inhibiting ubiquitin ligase MDM2. Nucleic Acids Res 2014; 42: 3565-79.; PMID: 24413661; http://dx. doi. org/10. 1093/nar/gkt1371.